The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Open accessAbstract
BACKGROUND: Azoles play an important role in the management of Aspergillus diseases. Azole resistance is an emerging global problem in Aspergillus fumigatus, and may develop through patient therapy. In addition, an environmental route of resistance development has been suggested through exposure to 14α-demethylase inhibitors (DMIs). The main resistance mechanism associated with this putative fungicide-driven route is a combination of alterations in the Cyp51A-gene (TR(34)/L98H). We investigated if TR(34)/L98H could have developed through exposure to DMIs. METHODS AND FINDINGS: Thirty-one compounds that have been authorized for use as fungicides, herbicides, herbicide safeners and plant growth regulators in The Netherlands between 1970 and 2005, were investigated for cross-resistance to medical triazoles. Furthermore, CYP51-protein homology modeling and molecule alignment studies were performed to identify similarity in molecule structure and docking modes. Five triazole DMIs, propiconazole, bromuconazole, tebuconazole, epoxiconazole and difenoconazole, showed very similar molecule structures to the medical triazoles and adopted similar poses while docking the protein. These DMIs also showed the greatest cross-resistance and, importantly, were authorized for use between 1990 and 1996, directly preceding the recovery of the first clinical TR(34)/L98H isolate in 1998. Through microsatellite genotyping of TR(34)/L98H isolates we were able to calculate that the first isolate would have arisen in 1997, confirming the results of the abovementioned experiments. Finally, we performed induction experiments to investigate if TR(34)/L98H could be induced under laboratory conditions. One isolate evolved from two copies of the tandem repeat to three, indicating that fungicide pressure can indeed result in these genomic changes. CONCLUSIONS: Our findings support a fungicide-driven route of TR(34)/L98H development in A. fumigatus. Similar molecule structure characteristics of five triazole DMIs and the three medical triazoles appear the underlying mechanism of cross resistance development. Our findings have major implications for the assessment of health risks associated with the use of triazole DMIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
A Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827
Blacklow, N. R., Gorbach, S. L., & Bartlett, J. G. (1992) · Cited by 2,753
Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking
Kramer, B., Rarey, M., & Lengauer, T. (1999) · Proteins: Structure, Function, and Genetics · doi:10.1002/(sici)1097-0134(19991101)37:2<228::aid-prot8>3.0.co;2-8 · Cited by 906
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Rosnow, R. L., & Rosenthal, R. (1996) · Psychological Methods · doi:10.1037/1082-989x.1.4.331 · Cited by 761
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Self-citationAzole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationPodust, L. M., Poulos, T. L., & Waterman, M. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061562898 · Cited by 531
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Self-citationClinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Self-citationPossible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Self-citationMultiple-Triazole–Resistant Aspergillosis
Verweij, P. E., Mellado, E., & Melchers, W. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmc061720 · Cited by 380
Self-citationDenning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313
Structural Basis of Human CYP51 Inhibition by Antifungal Azoles
Strushkevich, N., Usanov, S. A., & Park, H.-W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.01.075 · Cited by 270
de Valk, H. A., Meis, J. F. G. M., Curfs, I. M., Muehlethaler, K., Mouton, J. W., & Klaassen, C. H. W. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.4112-4120.2005 · Cited by 247
Self-citationMortensen, K. L., Mellado, E., Lass-Flörl, C., Rodriguez-Tudela, J. L., Johansen, H. K., & Arendrup, M. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00692-10 · Cited by 233
Lockhart, S. R., Frade, J. P., Etienne, K. A., Pfaller, M. A., Diekema, D. J., & Balajee, S. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-11 · Cited by 231
Hodiamont, C. J., Dolman, K. M., ten Berge, I. J. M., Melchers, W. J. G., Verweij, P. E., & Pajkrt, D. (2008) · Medical Mycology · doi:10.1080/13693780802545600 · Cited by 135
Self-citationAlanio, A., Sitterlé, E., Liance, M., Farrugia, C., Foulet, F., Botterel, F., Hicheri, Y., Cordonnier, C., Costa, J., & Bretagne, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq450 · Cited by 126
Brunner, P. C., Stefanato, F. L., & McDonald, B. A. (2008) · Molecular Plant Pathology · doi:10.1111/j.1364-3703.2007.00464.x · Cited by 120
Mavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Verweij, P. E., & Mouton, J. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00606-10 · Cited by 96
Self-citationAzole‐Resistant Central Nervous System Aspergillosis
van der Linden, J. W. M., Jansen, R. R., Bresters, D., Visser, C. E., Geerlings, S. E., Kuijper, E. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Clinical Infectious Diseases · doi:10.1086/597465 · Cited by 85
Self-citationKuipers, S., Brüggemann, R. J. M., de Sévaux, R. G. L., Heesakkers, J. P. F. A., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01544-10 · Cited by 41
Self-citationAn Improved Model of the Aspergillus fumigatus CYP51A Protein
Fraczek, M. G., Bromley, M., & Bowyer, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-10 · Cited by 40
Verweij, P. E., Camps, S. M. T., Kema, G. H. J., & Melchers, W. J. G. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr008 · Cited by 7
Self-citation
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Self-citationHow to bolster the antifungal pipeline
Denning, D. W., & Bromley, M. J. (2015) · Science · doi:10.1126/science.aaa6097 · Cited by 481
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Metadata
- Authors
- Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der Lee, H. A., Klaassen, C. H., Melchers, W. J. G., & Verweij, P. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-01
- Volume
- 7
- Issue
- 3
- Pages
- e31801
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2041015559
- Cited by
- 427
- References
- 27
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.